Table 1.
Effect of PHA-848125 on cell proliferation and autophagy or apoptosis induction
| Cell line | Mutations | Cell proliferation IC50 (μM) | BrdU incorporation inhibition (%)a | Autophagic cellsb (%)a | Cleaved caspase-3 positive cellsb (%)a | TUNEL positive cellsb (%)a |
|---|---|---|---|---|---|---|
| SF268 | EGFRvIII; p53; P16INK4a | 2.5 ± 0.6 | 78 | 70 | nt | nt |
| SF539 | PTEN; RB1 | 1.4 ± 0.5 | 39 | 35 | 8.7 | 10.3 |
| U251 | PTEN; p53; P16INK4a | 2.1 ± 0.8 | 74 | 58 | 0 | 0 |
| U87MG | PTEN; P16INK4a | 1.6 ± 0.8 | 92 | 52 | 0 | 0 |
a
Net values (subtracted of the value of control cells), obtained with a 3 μM treatment for 24 h.
b
Positive control were treated with 100 μM temozolomide for autophagy (positive cells: 19–27%) and with 1 μM camptothecin for apoptosis (positive cells: 23–86% for activated caspase and 30–87% for TUNEL).